Experimental Male Fertility Protocol Shared Online, Clinical Efficacy Unconfirmed

A new "experimental Male Fertility Small Molecule Protocol" has been shared on social media by content creator AJAC, sparking discussion within biohacking circles. The protocol suggests daily injections of 500mg of Carnitine for 12 weeks, 50mg of NAD+ daily for 10 days, and 5mg of MOTS-C injected three times weekly for four weeks, noting it is for those for whom "affordability is a non-issue" and who are "open to research." AJAC is known for sharing experimental performance and health optimization methods, and is not a medical doctor.

L-Carnitine, particularly L-carnitine and L-acetylcarnitine, has been widely studied for its potential benefits in male fertility. Research indicates it can improve sperm parameters such as motility, morphology, and concentration, primarily due to its antioxidant properties and role in mitochondrial function. Clinical trials have shown mixed results regarding its impact on natural conception rates, with some improvements noted in sperm quality at typical oral doses of 1 to 3 grams per day over several months.

Nicotinamide Adenine Dinucleotide (NAD+) levels are known to decline with age, a factor linked to impaired spermatogenesis and reduced sperm counts in animal models. Studies on NAD+ precursors like Nicotinamide Mononucleotide (NMN) and Nicotinic Acid (NA) have shown promise in restoring NAD+ levels and improving fertility in mice, particularly in cases of induced infertility. However, human evidence is less conclusive, and professional medical guidelines currently do not recommend NAD+ supplementation for infertility due to insufficient robust clinical data.

MOTS-C, a mitochondrial-derived peptide, has demonstrated potential in animal studies to ameliorate reproductive damage and influence key reproductive hormones. Its effects are linked to metabolic regulation, anti-inflammatory, and anti-apoptotic pathways. However, comprehensive human research on MOTS-C's direct impact on male fertility and the efficacy of specific dosages or injectable routes remains in early, experimental stages.

The protocol outlined by AJAC involves injectable forms and specific dosages that largely fall outside the scope of established human clinical trials. While the individual components are subjects of ongoing scientific investigation for various health benefits, their combined use in this specific "experimental" regimen for male fertility lacks broad clinical validation. Medical professionals advise caution with unproven protocols and emphasize consulting healthcare providers for fertility concerns.